PNC-27 peptide offers several potential benefits, primarily centered on its selective targeting and destruction of cancer cells. Its most notable benefit is its ability to selectively disintegrate the membranes of cancer cells, leading to necrosis (cell death) while sparing healthy cells, due to its specific binding to HDM-2 proteins found on cancer cell membranes but not on normal cells.
 This mechanism results in transmembrane pore formation, causing tumor cell lysis without relying on apoptosis, a common pathway for many anticancer agents.
 PNC-27 has demonstrated efficacy against a wide range of cancer types, including pancreatic, breast, ovarian, leukemia, and melanoma, both in vitro and in vivo.
 Additionally, it shows potential for synergistic effects with conventional chemotherapeutics like paclitaxel, enhancing overall antitumor activity.